Phase 3 LITESPARK-022: Pembrolizumab (pembro) plus hypoxia-inducible factor 2α (HIF-2α) inhibitor belzutifan as adjuvant treatment for clear cell renal cell carcinoma (ccRCC).
Year: 2023
Type: conference-abstract
Source: Journal of Clinical Oncology
Institutions: Harvard University, Dana-Farber Cancer Institute, University of Tübingen, The University of Texas MD Anderson Cancer Center, University of California San Diego, Memorial Sloan Kettering Cancer Center, City Of Hope National Medical Center, City of Hope, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology, Fox Chase Cancer Center, Merck & Co., Inc., Rahway, NJ, USA (United States), Queen Mary University of London, Barts Health NHS Trust, The Royal Free Hospital, Barts Cancer Institute
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4324136605